AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02966834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GSK2330672 matching placebo will be supplied as white film-coated tablets.
Study NCT02966834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: GSK2330672 matching placebo will be supplied as white film-coated tablets.
Study NCT02966834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330672
Description: GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.
Study NCT02351921 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Intermittent theta-burst stimulation is a form of repetitive Transcranial magnetic stimulation. ITBS is a non-invasive, non-painful procedure being used worldwide to study brain function and promote short-term changes (\~1 hour) in neural activity in the brain. The delivery of cTBS requires \~ 40 seconds in total.
Study NCT02351921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Intermittent theta-burst stimulation is a form of repetitive Transcranial magnetic stimulation. ITBS is a non-invasive, non-painful procedure being used worldwide to study brain function and promote short-term changes (\~1 hour) in neural activity in the brain. The delivery of cTBS requires \~ 40 seconds in total.
Study NCT03380286 — intervention group
Intervention type: DEVICE
Intervention: Firehawk
Description: Firehawk stent
Study NCT00544414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00544414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00544414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00544414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00544414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00544414 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Study NCT00544414 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Study NCT00544414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00544414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00544414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Study NCT00544414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00544414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00544414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT00544414 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03783637 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Whole grain oats
Description: A meal containing whole grain oats
Study NCT03783637 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Whole grain wheat
Description: A meal containing whole grain wheat
Study NCT00720499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL plus tiotropium bromide
Description: BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
Study NCT03888053 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BB-101
Description: Within each cohort, 8 subjects will be randomized to receive BB-101 and 4 subjects to receive placebo.
Study NCT04196127 — intervention group
Intervention type: OTHER
Intervention: Bite force testing
Description: Maximum bite force examination with a force intra-oral measuring device
Study NCT00720499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat® Inhaler
Study NCT02825823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Salt
Study NCT02825823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00611052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Adolescent Coping with Stress
Description: A group cognitive intervention, manualized and highly structured. Includes 8 sessions (á 1.5 hours) and a booster session 6 months after termination of the actual intervention. Groups leaders are specifically trained for this course.
Study NCT00611052 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The usual treatment received by the adolescent with mild to moderate self-reported depressive symptoms in school health care.
Study NCT00611052 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual health education
Description: usual health education given by the school nurses, targeted for healthy controls with no depressive symptoms according to the self-report scale
Study NCT01430377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SB predilatation
Description: Initial SB \[predilatation.
Study NCT01430377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No SB predilatation
Description: Without SB predilatation
Study NCT03432260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUR-928 30 mg
Description: Lowest dose of 3 dose escalation arms.
Study NCT03432260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUR-928 90 mg
Description: Middle dose of 3 dose escalation arms.
Study NCT03432260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUR-928 150 mg
Description: Highest dose of 3 dose escalation arms.
Study NCT00914368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients not already on clopidogrel treatment a loading dose of clopidogrel 600 mg followed by a maintenance dose of 75 mg once daily will be administered.
Study NCT00427310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00427310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Study NCT00427310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium heparin
Study NCT03543800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytorich PRP kit
Description: Subjects randomized to the PRP treatment arm will receive PRP only without the anti-inflammatory component of ABP added
Study NCT03543800 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PRP kit
Description: PRP kit legally marketed in Canada for PRP
Study NCT02852070 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bronchoalveolar lavage 120ml
Description: 120mL sterile saline solution instilled into the distal bronchial tree in 3 times
Study NCT02852070 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchoalveolar lavage 60ml
Description: 60mL sterile saline solution instilled into the distal bronchial tree in 3 times
Study NCT04150315 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Proteome analysis
Description: Evaluation of specific protein levels in tissue and plasma.
Study NCT03463083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: All cases of spine surgery will be done under G.A with the patient in prone position. After surgery an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~1. The pain score, by using VAS~2. Onset of analgesia (fall of VAS\<4 ).~3. Peak level of analgesia ( VAS score 0).~4. Duration of analgesia (once the patient asks fwith VAS>4).~5. Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~6. Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale>1 Also deep sedation Ramsay sedation scale>3 , And shivering and hypotension.
Study NCT03463083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: All cases of spine surgery will be done under G.A with the patient in prone position. After surgury an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~1. The pain score, by using VAS~2. Onset of analgesia (fall of VAS\<4 ).~3. Peak level of analgesia ( VAS score 0).~4. Duration of analgesia (once the patient asks fwith VAS>4).~5. Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~6. Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale>1 Also deep sedation Ramsay sedation scale>3 , And shivering and hypotension.
Study NCT03463083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: All cases of spine surgery will be done under G.A with the patient in prone position. After surgury an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~1. The pain score, by using VAS~2. Onset of analgesia (fall of VAS\<4 ).~3. Peak level of analgesia ( VAS score 0).~4. Duration of analgesia (once the patient asks fwith VAS>4).~5. Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~6. Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale>1 Also deep sedation Ramsay sedation scale>3 , And shivering and hypotension.
Study NCT03335046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Visit
Description: The intervention will consist of a series of home visitations to chronically absent students with co-morbid asthma. These visits will consist of a home environment evaluation, medication adherence and knowledge assessment, distribution of home environmental allergen reduction items such as mattress and pillow encasements, as well as review and reinforcement of any asthma action plans or care plans provided by patient's primary care physicians or medical home.
Study NCT03335046 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Home Visit
Description: The intervention will consist of a series of home visitations to chronically absent students with co-morbid asthma. These visits will consist of a home environment evaluation, medication adherence and knowledge assessment, distribution of home environmental allergen reduction items such as mattress and pillow encasements, as well as review and reinforcement of any asthma action plans or care plans provided by patient's primary care physicians or medical home.
Study NCT03335046 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Standard care will refer to the procedures carried out by the school district to address students with chronic absenteeism. This includes parent-teacher and parent-school administrator meetings and communications and may also include home visits carried out by classroom teachers or student support center staff.
Study NCT03531749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HIV+ MRPJ
Description: supplemented with (1g/d) MRPJ
Study NCT03531749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HIV+ ascorbic acid
Description: Supplemented with (1g/d) AA
Study NCT04872283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: great toe (1st metatarsophalangeal joint) fusion
Description: Great Toe joint fusion surgery
Study NCT06609993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous rescue opioid analgesia using fentanyl
Description: intraoperative rescue opioid analgesia using 1mcg/kg of fentanyl (Fentanyl WZF, POlfa Warsawa, Poland) )/ body weight when SPI value > 15 baseline
Study NCT04872283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Ketorolac
Description: Participants will receive 30mg of intravenous (IV) ketorolac will be given during surgery
Study NCT04872283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Pill
Description: Participants will receive 20 tablets of 10mg ketorolac, with instructions to take 1 tablet orally every 6 hours for pain
Study NCT04872283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5/325mg Oxycodone-Acetaminophen
Description: Participants will receive 30 tablets of 5/325mg oxycodone-acetaminophen with instructions to take 1 or 2 tablets by mouth every 4 to 6 hours as needed for pain
Study NCT04872283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81Mg Ec Tab
Description: Participants will receive 81 mg aspirin twice daily as a preventive measure against deep venous thrombosis (DVT)
Study NCT02160938 — intervention group
Intervention type: OTHER
Intervention: 3-year follow-up
Description: When the infants reach 24 months of age, the Study Follow-up Specialist will send all participants an age- appropriate Ages and Stages Questionnaire (ASQ) for completion.~At the age of 3, the following exams will be performed and are described below:~* The Vineland-II Adaptive Behavior Scale (VABS)~* Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV), or Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V, for siblings older than 7 years 7 months, when necessary)~* Children will also be photographed (for review by the study dysmorphologist)
Study NCT01132508 — intervention group
Intervention type: DEVICE
Intervention: Norian Drillable Bone Void Filler
Description: Norian Drillable Bone Void Filler is a moldable, biocompatible bone void filler with added reinforcing fibers. Norian Drillable is intended to be placed into bony voids either before or after final fixation. The material can be drilled and tapped, and screws can be placed through it at any time during the setting process. Norian Drillable is a composite, two-component, self-setting calcium phosphate bone void filler
Study NCT01716273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Granulated Sugar
Description: 30 grams of granulated sugar is used to cover the wound area and this is held in place using a dry dressing pad , bandage and tape.
Study NCT01716273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Granulated Sugar
Description: 30 grams of granulated sugar is used to cover the wound area and this is held in place using a dry dressing pad , bandage and tape.
Study NCT01716273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Debridement Dressing
Description: 1 Aquacel or Sorbsan dressing will be put over the wound, and held in place with a dry dressing pad, bandage and tape.
Study NCT01716273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Debridement Dressing
Description: 1 Aquacel or Sorbsan dressing will be put over the wound, and held in place with a dry dressing pad, bandage and tape.
Study NCT06609993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous rescue atropine administration
Description: atropine (Atropinum Sulfuricum WZF, POlfa Warsawa, Poland) in a dose of 0,5mg/kg of will be administered intravenously when heart rate \< 50
Study NCT01911741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDV3100
Description: Oral
Study NCT06609993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous rescue urapidil administration
Description: urapidil (Ebrantil 25, Takeda PHARMA, Japan) in a dose of 10 mg will be administered intravenously when DAP > 110 mmHg or SAP > 200 mmHg
Study NCT01020123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Different doses of AZD1656 administered to 5 groups of patients
Study NCT01020123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: AZD1656 placebo and glipizide placebo administered to 1 group of patients
Study NCT01020123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Description: Glipizide administered to 1 group of patients
Study NCT02857868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL001
Study NCT01535885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytotoxic T Lymphocytes
Description: Patients will be studied in cohorts of 3. Eligible patients will receive a single Multi-Virus CTL line infusion 28-100 days after their transplant. The dose will start at dose level 1 (2.0 x 106/kg). After each cohort of 3 patients has been treated at each of the dose levels, decisions will be made if the next high or lower dose level should be used.
Study NCT04434508 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic right hemicolectomy with CME and central v
Description: laparoscopic right hemicolectomy with CME and central v
Study NCT04434508 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open right hemicolectomy with CME and central v
Description: Open right hemicolectomy with CME and central v
Study NCT04289909 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Adaptive Optics Ophthalmoscopy (AOO)
Description: AOO will permit to detect and quantify retinal perivascular inflammation in patients with MS in comparison to Healthy volunteers (control group)
Study NCT02866643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel-Immediate
Description: The investigational intervention will be to insert the contraceptive implant immediately postpartum in the delivery room insertion (0-2 hours following delivery).
Study NCT02866643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel-Delayed
Description: The investigational intervention will be to insert the contraceptive implant 24-48 hours following delivery.
Study NCT01162200 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy
Description: 3 dose cohorts. Patients in each dose cohort will all be treated as a single group for dose escalation. The starting dose for the dose escalation portion will be 6 Gy per fraction for 5 fractions (total dose = 30 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per treatment (total 2.5 Gy per escalation).
Study NCT03684746 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: It is an observational Study with staff
Study NCT00825240 — intervention group
Intervention type: BEHAVIORAL
Intervention: One-time Questionnaire + Recorded Qualitative Interview
Description: One-time questionnaire + recorded qualitative interview, approximately 45 minutes total.
Study NCT02394769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT02394769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Aspirin
Study NCT04066374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: Medtronic Intellis Spinal Cord Stimulation Device to be implanted in thoracic cavity to treat postoperative acute pain.
Study NCT00587093 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CA 125 and CT scan
Description: Within 14 days prior to surgery serum for CA125 will be obtained. The patient will also undergo a CT scan of the abdomen and pelvis with oral and intravenous contrast within 35 days prior to the procedure.
Study NCT03778671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Patients will receive Levobupivacaine 5%
Study NCT03778671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: Patients will receive Levobupivacaine 5% + 1 µg/kg dexmedetomedine
Study NCT03778671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: Patients will receive Levobupivacaine 5% + 1 µg/kg fentanyl
Study NCT01273259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA Treatment
Description: DHEA : 200 mg/day hard gelatine capsule
Study NCT01273259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA Treatment
Description: DHEA : 25 mg/day hard gelatine capsule
Study NCT04328987 — intervention group
Intervention type: PROCEDURE
Intervention: cold snare polypectomy
Description: Resection of colorectal polyp using cold snare polypectomy method. The polyp will be resected by mechanical force of snare without electrical cautery.
Study NCT01683461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Counseling
Description: Women in the enhanced counseling arm receive the following intervention package: a video prior to their HIV pre-test counseling session that prepares them for decisions they will have to make regarding HIV testing and PMTCT participation, a pre-test counseling session and post-test counseling session with their nurse midwife/counselor, and two additional post-test counseling sessions with the same nurse midwife at 6 and 10 weeks postpartum. Women in the enhanced counseling arm also have access to ongoing support groups and legal support if needed at the clinic.